Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia

Marvin M. van Luijn; Willemijn van den Ancker; S. Marieke van Ham; Arjan A. van de Loosdrecht

doi:10.4161/21624011.2014.941737

Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia

Marvin M. van Luijn, Willemijn van den Ancker, S. Marieke van Ham, Arjan A. van de Loosdrecht^*

^*Corresponding author for this work

Immunology

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

25 Downloads (Pure)

Abstract

The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.

Original language	English
Pages (from-to)	1-3
Number of pages	3
Journal	OncoImmunology
Volume	3
Issue number	12
DOIs	https://doi.org/10.4161/21624011.2014.941737
Publication status	Published - 2 Dec 2014

Bibliographical note

Publisher Copyright:
© 2014 Taylor & Francis Group, LLC.

Access to Document

10.4161/21624011.2014.941737

Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemiaFinal published version, 459 KB

Cite this

@article{881981a02f134739a29935c650d6092d,

title = "Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia",

abstract = "The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.",

author = "{van Luijn}, {Marvin M.} and {van den Ancker}, Willemijn and {van Ham}, {S. Marieke} and {van de Loosdrecht}, {Arjan A.}",

note = "Publisher Copyright: {\textcopyright} 2014 Taylor & Francis Group, LLC.",

year = "2014",

month = dec,

day = "2",

doi = "10.4161/21624011.2014.941737",

language = "English",

volume = "3",

pages = "1--3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "12",

}

TY - JOUR

T1 - Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia

AU - van Luijn, Marvin M.

AU - van den Ancker, Willemijn

AU - van Ham, S. Marieke

AU - van de Loosdrecht, Arjan A.

PY - 2014/12/2

Y1 - 2014/12/2

N2 - The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.

AB - The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.

UR - http://www.scopus.com/inward/record.url?scp=84938781652&partnerID=8YFLogxK

U2 - 10.4161/21624011.2014.941737

DO - 10.4161/21624011.2014.941737

M3 - Article

C2 - 25964856

AN - SCOPUS:84938781652

SN - 2162-4011

VL - 3

SP - 1

EP - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 12

ER -

Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this